TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial
Open Access
- 15 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (14), 3732-3739
- https://doi.org/10.1158/1078-0432.ccr-19-3034
Abstract
We performed next-generation sequencing (NGS) in the CONKO-001 phase III trial to identify clinically relevant prognostic and predictive mutations and conducted a functional validation in The Cancer Genome Atlas (TCGA) sequencing data. Patients of the CONKO-001 trial received curatively intended surgery for pancreatic adenocarcinoma (PDAC) followed by adjuvant chemotherapy with gemcitabine (Gem) or observation only (Obs). Tissue samples of 101 patients were evaluated by NGS of 37 genes. Cox proportional hazard models were applied for survival analysis. In addition, functional genomic analyses were performed in an NGS and RNA-sequencing dataset of 146 pancreatic tumors from TCGA. The most common mutations in the CONKO cohort were KRAS (75%), TP53 (60%), SMAD4 (10%), CDKNA2 (9%), as well as SWI/SNF (12%) complex alterations. In untreated patients, TP53 mutations were a negative prognostic factor for disease-free survival (DFS; HR mut vs. WT 2.434, P = 0.005). With respect to gemcitabine treatment, TP53 mutations were a positive predictive factor for gemcitabine efficacy [TP53mut: HR for DFS Gem vs. Obs, 0.235 (0.130 – 0.423; P < 0.001); TP53wt: HR for DFS Gem vs. Obs, 0.794 (0.417 – 1.513; P = 0.483)] with a significant test for interaction (P = 0.003). In the TCGA dataset, TP53 mutations were associated with shortened DFS. In CONKO-001, the benefit from adjuvant gemcitabine was confined to the TP53mut patient group. This potentially clinical relevant observation needs to be confirmed in independent prospective studies. The sensitivity of TP53mut PDAC to gemcitabine in CONKO-001 provides a lead for further mechanistic investigations.Keywords
Funding Information
- German Cancer Consortium (NGS_CONKO-001)
- Berlin Institute of Health (NGS_CONKO-001)
- Charite Universitaetsmedizin Berlin; Rahel Hirsch Grant (NGS_CONKO-001)
This publication has 24 references indexed in Scilit:
- Does long-term survival in patients with pancreatic cancer really exist?-Results from the CONKO-001 studyJournal of Surgical Oncology, 2013
- Existing and Emerging Technologies for Tumor Genomic ProfilingJournal of Clinical Oncology, 2013
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Mutant p53: one name, many proteinsGenes & Development, 2012
- The history of p53EMBO Reports, 2010
- KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics: Comparison of Methods and Impact of HistologyThe Journal of Molecular Diagnostics, 2010
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer TreatmentJournal of Clinical Oncology, 2009
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- p53 gain-of-function cancer mutants induce genetic instability by inactivating ATMNature, 2007
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI Journal of the National Cancer Institute, 2005